Celiac Disease

Teva reported positive results in a clinical trial for the treatment of celiac disease. The trial met its primary endpoint, demonstrating that the TEV-408 antibody prevents intestinal damage.

The company reports success in a clinical trial for a drug that blocks an inflammatory protein. The treatment is intended for two different conditions and is expected to advance to later development stages soon.